Papillomavirus Infections: all 505 studies

Page 2 of 6. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.

• Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)RecruitingNCT05672927Phase 4
• Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous WartsRecruitingNCT05625633Phase 2/3
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingNCT05592626Phase 1/2
• Human Papillomavirus in Young People Epidemiological Research 3RecruitingNCT05587725
• Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive WomenRecruitingNCT05570331
• Diagnostic Cervical Conization for Persistent Infection or Integration of HPVNot yet recruitingNCT05510830Not applicable
• Immunogenicity of 9-valent HPV VaccineRecruitingNCT05439083Phase 4
• Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx CancerRecruitingNCT05388773Phase 2
• Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV VaccineRecruitingNCT05371353
• PCOM2 - The Physician Communication Intervention, Version 2.0RecruitingNCT05336240Not applicable
• A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)RecruitingNCT05334706Phase 4
• The Organ Transplant Recipient HPV and Skin Cancer StudyRecruitingNCT05284877
• Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV InfectionRecruitingNCT05283239
• A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSILRecruitingNCT05282745
• Effect of HPV Integration on Prognosis of Young Women With CIN2 in ChinaRecruitingNCT05282095
• Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIVRecruitingNCT05266898Phase 4
• A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsRecruitingNCT05262010Phase 3
• Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY TrialNot yet recruitingNCT05173324Phase 3
• HPV Viral Load in Predicting the Prognosis of LSILRecruitingNCT05051852
• Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 YearsRecruitingNCT05027776Phase 3
• Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in TanzaniaRecruitingNCT04953130Phase 4
• Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in SwedenRecruitingNCT04910802Phase 4
• Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 YearsRecruitingNCT04895020Phase 3
• Evaluation of AHCC® for the Clearance of High Risk-HPV Infections in Chinese FemaleRecruitingNCT04633330Not applicable
• Self-sampling for Non-attenders to Cervical Cancer ScreeningRecruitingNCT04226313Not applicable
• Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)RecruitingNCT04098744Phase 2
• Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICINRecruitingNCT04057924
• Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility TrialNot yet recruitingNCT03429413Not applicable
• Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American CountriesActive, not recruitingNCT06002126Not applicableResults posted
• HPV Self-Sampling in Somali Women (Isbaar Project)CompletedNCT05453006Not applicableResults posted
• Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and TelemedicineCompletedNCT05340322Not applicableResults posted
• Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)CompletedNCT05119855Phase 3Results posted
• 1:1 Comparison of the Pocket Colposcope in KenyaCompletedNCT04998318Not applicableResults posted
• Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)CompletedNCT04772534Phase 3Results posted
• Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer TrialCompletedNCT04679675Not applicableResults posted
• Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE StudyCompletedNCT04660331Not applicableResults posted
• Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIVCompletedNCT04587050Results posted
• HPV Typing Between Self- and Physician-sampledCompletedNCT04472377Not applicableResults posted
• Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in AppalachiaCompletedNCT04411849Not applicableResults posted
• Thermocoagulation for Treatment of Precancerous Cervical LesionsCompletedNCT04191967Not applicableResults posted
• HPV-Based Screen-and-Treat Demonstration Project in LilongweCompletedNCT04092257Not applicableResults posted
• E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal CancerTerminatedNCT04015336Phase 2Results posted
• A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital WartsCompletedNCT03981822Phase 2Results posted
• Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)CompletedNCT03903562Phase 3Results posted
• Prospective Evaluation of Self-Testing to Increase ScreeningCompletedNCT03898167Not applicableResults posted
• The Human Papilloma Virus Effect on Sexual LifeCompletedNCT03837028Results posted
• M7824 in People With Recurrent Respiratory PapillomatosisCompletedNCT03707587Phase 2Results posted
• Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual BloodCompletedNCT03638427Results posted
• Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the CervixTerminatedNCT03610581Phase 1/2Results posted
• Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)CompletedNCT03546842Phase 3Results posted
• Cantharidin and Occlusion in Verruca EpitheliumCompletedNCT03487549Phase 2Results posted
• Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)CompletedNCT03158220Phase 3Results posted
• Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant RecipientsActive, not recruitingNCT03036930Phase 2Results posted
• Avelumab for People With Recurrent Respiratory PapillomatosisCompletedNCT02859454Phase 2Results posted
• E7 TCR T Cells for Human Papillomavirus-Associated CancersCompletedNCT02858310Phase 1/2Results posted
• Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx CancerTerminatedNCT02827838Early Phase 1Results posted
• BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck CancerTerminatedNCT02706691Phase 2Results posted
• Safety and Tolerability Study of V501 in Japanese Boys (V501-200)CompletedNCT02576054Phase 3Results posted
• Lubricant Investigation in Men to Inhibit Transmission of HPV InfectionTerminatedNCT02354144Phase 2/3Results posted
• Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal CancerCompletedNCT02258659Phase 2Results posted
• Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade LesionsCompletedNCT02135419Phase 3Results posted
• A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)CompletedNCT02114385Phase 3Results posted
• Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV VaccinationCompletedNCT02003508Results posted
• A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)CompletedNCT01984697Phase 3Results posted
• Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIVCompletedNCT01946139Not applicableResults posted
• Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal CancerCompletedNCT01932697Phase 2Results posted
• Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal CancerActive, not recruitingNCT01898494Phase 2Results posted
• Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)CompletedNCT01862874Phase 3Results posted
• Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) StudyCompletedNCT01824537Phase 4Results posted
• Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical CancerCompletedNCT01693783Phase 2Results posted
• Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer SurvivorsCompletedNCT01492582Phase 2Results posted
• Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal CancerCompletedNCT01302834Phase 3Results posted
• A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).CompletedNCT01254643Phase 3Results posted
• GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)CompletedNCT01245764Phase 3Results posted
• Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)CompletedNCT01078220Results posted
• GARDASIL™ Vaccine Impact in Population Study (V501-033)CompletedNCT01077856Results posted
• A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)CompletedNCT01073293Phase 3Results posted
• Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)CompletedNCT01020747Phase 1Results posted
• A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)CompletedNCT00988884Phase 3Results posted
• Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the HandsCompletedNCT00973856Not applicableResults posted
• Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® SystemCompletedNCT00973362Phase 3Results posted
• A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)CompletedNCT00943722Phase 3Results posted
• Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in VenezuelaCompletedNCT00937547Results posted
• Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex WorkersCompletedNCT00925288Phase 4Results posted
• Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)CompletedNCT00834106Phase 3Results posted
• Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")TerminatedNCT00747461Phase 4Results posted
• A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.TerminatedNCT00730847Phase 4Results posted
• An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)CompletedNCT00635830Phase 1Results posted
• Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University SettingCompletedNCT00572832Not applicableResults posted
• Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory PapillomatosisCompletedNCT00571701Phase 2Results posted
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of AgeCompletedNCT00552279Phase 3Results posted
• Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)CompletedNCT00543543Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In AdolescentsCompletedNCT00518180Phase 3Results posted
• An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)CompletedNCT00496626Phase 3Results posted
• V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)CompletedNCT00411749Phase 2Results posted
• Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)CompletedNCT00380367Phase 3Results posted
• V501 Efficacy Study in Women Aged 18 to 26 (V501-027)CompletedNCT00378560Phase 2Results posted
• Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)CompletedNCT00365716Phase 2Results posted
• Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 VaccineCompletedNCT00316706Phase 3Results posted
• Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial NeoplasiaCompletedNCT00303823Phase 2Results posted

← Papillomavirus Infections overview